Peginterferón alfa-2b y Ribavirina en pacientes coinfectados VIH-VHC: eficacia y seguridad en la práctica clínica habitual
- Castelo Corral, Laura
- López Calvo, Soledad
- Castro Iglesias, Ángeles
- Vázquez Rodríguez, Pilar
- Bello Rodríguez, Laura
- Pedreira Andrade, José Domingo
ISSN: 0304-4866, 1989-3922
Year of publication: 2010
Volume: 71
Issue: 4
Pages: 161-168
Type: Article
More publications in: Galicia Clínica
Abstract
OBJECTIVE: To determine, in routine clinical practice, the efficacy and safety of peginterferon (PEG-IFN) plus ribavirin (RBV) in HCV-HIV co-infected patients in terms of sustained virologic response (SVR) and early discontinuation due to adverse effects. MATERIAL AND METHOD: Retrospective study with inclusion of all coinfected patients who started treatment with PEG-IFN �¿-2b and RBV between November/2002 and April/2007 in a specific hospital outpatient clinics. RESULTS: Forty-five patients were included (73% men; mean age: 39,8 �} 4,7 years). The median CD4 cell count was 593/mm3 and 62,3% were receiving HAART. The most common HCV genotypes were 1 (48,9%) and 3 (33,3%). HCV-RNA was . 5,7 log10 copies/ml in 85,4%. The SVR rate, in intention-to-treat analysis, was 22,2% (10/45). The SVR was significantly higher in two groups: patients with HCV genotype 3 (OR 7, p 0,021) and patients without HAART (OR 0,18, p 0,045). The toxicity leading to reduction of dose of drugs occurred in 22,2% and to discontinuation treatment occurred in 13,3%. There were no treatment-related deaths. Although HAART was discontinued in 6 patients and the absolute CD4 cell count fell by 293 CD4 cells/mm3, there were no opportunistic infections. CONCLUSIONS: In our clinical experience, SVR rate with PEG-IFN plus RBV in co-infected patients was low, even though, tolerance to treatment was acceptable with a rate of discontinuations due to toxicity similar to other series.